ACETAdicet Bio, Inc.

Nasdaq adicetbio.com


$ 1.66 $ -0.08 (-4.62 %)    

Wednesday, 08-May-2024 15:59:55 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 1.65
$ 1.70
$ 0.00 x 0
$ 0.00 x 0
$ 1.64 - $ 1.74
$ 1.10 - $ 7.50
998,685
na
71.02M
$ 1.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-19-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-15-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-15-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-17-2021 03-31-2021 10-Q
13 03-12-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 07-31-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-12-2020 12-31-2019 10-K
18 11-05-2019 09-30-2019 10-Q
19 08-14-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 03-18-2019 12-31-2018 10-K
22 11-13-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-reiterates-outperform-on-adicet-bio-maintains-5-price-target

Wedbush analyst Robert Driscoll reiterates Adicet Bio (NASDAQ:ACET) with a Outperform and maintains $5 price target.

 hc-wainwright--co-maintains-buy-on-adicet-bio-maintains-10-price-target

HC Wainwright & Co. analyst Edward White maintains Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.

 adicet-bio-may-offer-and-sell-shares-of-common-stock-having-an-aggregate-offering-price-of-up-to-100m-from-time-to-time

-SEC Filing

 hc-wainwright--co-reiterates-buy-on-adicet-bio-maintains-10-price-target

HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.

 wedbush-reiterates-outperform-on-adicet-bio-maintains-5-price-target

Wedbush analyst Robert Driscoll reiterates Adicet Bio (NASDAQ:ACET) with a Outperform and maintains $5 price target.

 canaccord-genuity-reiterates-buy-on-adicet-bio-maintains-19-price-target

Canaccord Genuity analyst John Newman reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $19 price target.

 adicet-bio-q4-earnings-insights
Adicet Bio: Q4 Earnings Insights
03/19/2024 21:30:06

 adicet-bio-q4-2023-gaap-eps-069-beats-070-estimate

Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.70) by...

 hc-wainwright--co-maintains-buy-on-adicet-bio-lowers-price-target-to-10

HC Wainwright & Co. analyst Edward White maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from ...

 adicet-bio-prices-public-offering-of-27054667-common-shares-at-240share-and-pre-funded-warrants-to-purchase-8445333-common-shares-at-23999pre-funded-warrant

The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expect...

 why-jetblue-airways-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of JetBlue Airways Corporation (NASDAQ: JBLU) fell sharply during Tuesday’s session.

 why-mobileye-global-shares-are-trading-lower-by-over-23-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23...

 adicet-bio-sets-2024-goals-advancing-allogeneic-gamma-delta-t-cell-therapies-in-oncology-and-autoimmune

Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell...

 adicet-bio-highlighted-adi-001-expansion-persistence-and-pharmacodynamic-profile-from-ongoing-phase-1-study-at-the-65th-american-society-of-hematology-ash-annual-meeting

ADI-001 showed robust dose-dependent expansion and persistence in patients with relapsed/refractory aggressive B-cell non-Hod...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION